<head>
  <meta charset="UTF-8">
</head>
        <p style="text-align:start;hyphenate:auto;font-family:Times New Roman;font-size:12pt;">
            <span style="font-weight:bold;">NSCLC/PIK3CA/E545K	</span>
        </p>
        <p style="text-align:start;hyphenate:auto;font-family:Times New Roman;font-size:12pt;">
            <span style="font-style:italic;color:black;">PIK3CA</span><span style="color:black;">  p110α/β/δ/γ  is an oncogene that encodes the catalytic subunit of the phosphatidylinositol 3- kinase (PI3K) protein, which is an integral part of the PI3K/Akt signaling pathway. </span><span style="font-style:italic;color:black;">PIK3CA</span><span style="color:black;"> is mutated in 1-4% of non-small cell lung cancers [PMID: 16930767, PMID: 15016963, PMID: 25473901]. </span><span style="font-style:italic;color:black;">PIK3CA</span><span style="color:black;"> c.1633G&gt;A is a missense mutation in the highly conserved helical domain and yields a glutamic acid to a lysine change (E545K). The PIK3CA E545K mutation accounts for 26.7% of all PIK3CA mutations in NSCLCs [COSMIC]. This mutation has increased catalytic activity, which leads to enhanced activation of downstream signaling pathways [PMID: 15647370]. </span>
        </p>
        
        <p style="text-align:start;hyphenate:auto;font-family:Times New Roman;font-size:12pt;">
            <span style="font-weight:bold;">NSCLC/PIK3CA/E545K/Buparlisib (BKM120) (score R)</span>
        </p>
        <p style="text-align:start;hyphenate:auto;font-family:Times New Roman;font-size:12pt;">
            <span>Buparlisib is a small molecule pan-PI3K inhibitor of p110α/β/δ/γ [PMID: 24900266]. A phase II clinical trial evaluating buparlisib in pretreated metastatic NSCLCs displaying PI3K pathway activation including PIK3CA E545K mutation showed no significant improved PFS [PMID: 26098748].</span>
        </p>
        
        <p style="text-align:start;hyphenate:auto;font-family:Times New Roman;font-size:12pt;">
            <span style="font-weight:bold;">NSCLC/PIK3CA/E545K/PI-103 (score 4)</span>
        </p>
        <p style="text-align:start;hyphenate:auto;font-family:Times New Roman;font-size:12pt;">
            <span>PI-103 is a small molecule multi-targeted inhibitor of PI3K (p110α/β/δ/γ) and mTOR [PMID: 16647110, PMID: 16697955, PMID: 19584227]. Preclinical data shows a NSCLC cell line, H460, which harbors PIK3CA E545K mutation, is more sensitive to PI-103 than another NSCLC cell line, which harbors wild-type PIK3CA [PMID: 19513541]. </span>
        </p>
    